-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Processa Pharmaceuticals, Lowers Price Target to $2

Benzinga·06/30/2025 10:57:56
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharmaceuticals (NASDAQ:PCSA) with a Buy and lowers the price target from $6 to $2.